These findings led to FDA approval for PD-L1 expression and provided the basis for subsequent trials such as KEYNOTE-010 (cut-off ≥1%) and KEYNOTE-024 (cut-off ≥50%) in NSCLC (4, 47). Here, CD274 is linked to non-small cell lung carcinoma.